Market Research Reports - Ken Research Global Cardiovascular Disease Drugs Market to 2023

Global Cardiovascular Disease Drugs Market to 2023: Ken Research
Global Cardiovascular Disease Drugs Market to 2023-Expiries, Acquisitions and New Products
for Deep Vein Thrombosis, Pulmonary Arterial Hypertension and Dyslipidemia to Shake-Up the
Competitive Landscape
The Cardiovascular Disease (CVD) therapy area encompasses a range of different diseases and
conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are
hypertension and dyslipidemia, which accelerate the development of atherosclerotic plaque
buildup within blood vessels. As atheroma develops it causes the affected blood vessels to
narrow, restricting blood flow to the body, brain or heart, depending on its locale. It is also
possible for the fibrous cap of this plaque to break off, triggering the coagulation cascade and
causing a thrombus to form locally, which can completely occlude blood flow.
The treatments of CVD typically focus on prevention by controlling risk factors. As such, the
treatments usually fall within three categories: Anti-hypertensives, which aim to maintain blood
pressure within a normal range; anti-dyslipidemic drugs, which aim to modify lipid levels to a
normal range; and anti-thrombotic drugs, which aim to prevent thrombi formation by inhibiting
the coagulation cascade or platelet aggregation.
There has been vast scientific innovation in the CVD therapeutics market in recent decades,
particularly within the anti-dyslipidemia market. This was seen first with the introduction of
statins such as Lipitor (atorvastatin), and more recently with the introduction of protein
convertase subtilisin/kexin type 9 (PCSK9) inhibitors. However, other areas such as the heart
failure market remain poorly treated. Dyslipidemia and hypertension have continuing high
levels of development within the current pipeline and, despite high levels of generic
development, there is also a large degree of innovation, with targets such as apolipoproteins
and elements of the reverse lipid transport pathway. In addition, the current pipeline includes
nearly 200 products for the treatment of heart failure, suggesting an increase in interest in
treating the disease.
With over 1,400 products in active development, the pipeline for CVD is extensive. Does current
pipeline innovation hold the potential to change the CVD market in the near future? The clinical
trials process for CVD drugs is complex. What is the risk of a CVD drug failing to reach the
market? What is the risk of a drug failing at a specific Phase? The CVD market landscape is
forecast to undergo a period of substantial change following key approvals, patent expiries and
acquisitions. Which of the leading companies will have the highest market share by 2023? What
strategies have these companies adopted to achieve market growth? There has been a
moderately high level of deal activity in recent years. How do deal frequency and value
compare between target families and molecule types?